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Opiates are known to produce various physiological effect s. Ou r understanding of
these effects has been greatly increased by the discovery of the opiat e receptor and the
endogenous opioid peptides. Recent investigation has demonstrat ed that th ree dist inct
receptor subtypes exist ; their function is currently being activel y investigated.
Receptor theory holds that a drug's actions are the result of interactions between
that drug and specific receptor molecules on the cell 's surface. The location of the
receptors in the body and the number of drug molecules that inter act with them are
important in determining the drug's effects. Vari ations in the dru g's chemical
structure will vary its affinity for the receptor. Thi s relationship is the basis of st ructure
activity relationships (SAR), a tool used by medicinal chemists when designing drugs.
Ideally a drug will have high specificity and affinity for one type of recept or. In the
field of psychopharmacology this ideal has not been achieved. Chlorpromazine, for
example, interacts with cholinergic and alpha-adrenergic receptors to produce anti-
cholinergic and orthostatic hypotensive effects as well as dopamine receptors to
produce its desired antipsychotic effects. The challenge to drug designers is the
synthesis of chemicals which interact with only one receptor to provide the desired
effect.
Narcotic analgesics also have side effects. Morphine, a prototypical narcot ic
analgesic, has associated hypotensive and respiratory depressant effects which are
considered disadvantageous. The narcotic antagonist naloxone has had a great impact
on the practice of medicine, and research on the opiate receptor and endogeno us
opiates. Clinically, it is used to reverse respiratory depression in narcotic overdoses.
Prior to naloxone, nalorphine could be used when a patient was brought into an
emergency room with narcotic-induced respiratory depression. Nalorphine, though,
has both narcotic agonist and antagonist properties. An analgesic when given alone, it
antagonizes the analgesic effects of morphine when given concomitantl y with
morphine. The fact that one drug could have two seemingly opposite effects prompted
researchers to investigate the possibility that more than one opiate recep tor existed. On
a tissue level, much research has been done trying to elucidate the possibility of
multiple opiate receptors. Paterson, Robsen, and Kosterlitz ( I) in a recent review
present the biochemical data indicating the existance of three distinct opiate receptors:
mu, kappa, and delta . Evidence for three distinct opiate receptors comes from the
competitive displacement of tritiated ligands from receptors by unlabelled ligand .
Binding assays have shown maximum binding capacities (i.e. sa tura bility) of the
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different receptors by highly selective ligands. Differences in distribution patterns
throughout the nervous system and the ability to selectively protect receptor subtypes
from alkylation are further evidence of three distinct opiate receptors . Studying the
role of each receptor is possible using receptor selective ligands. Few ligands are
completely specific for one receptor and overlap exists. Medicinal chemists are
attempting to synthesize more specific molecules and peptides.
Armed with these findings, researchers have been curious about the function of
each receptor. For example, U 50,488, an experimental analgesic drug (2) , relieves
pain but not evidentally by binding, as morphine does, to mu recep tors, but instead to
kappa receptors . Analgesia produced by U 50,488 is reversed by naloxone, however, it
lacks the morphine-type physical dependence. And while tolerance to the analgesic
effect develops there is no cross tolerance to morph ine. These findings with U 50,488
raise the question of mu receptor involvement in the physical dependance seen with
morphine.
The mouse vas deferens preparation is felt to be a good assay of delta receptor
activity. ICI 154,129 , a selective delta receptor antagonist in the mouse vas deferen s
preparation, does not produce the mu receptor mediated Straub tail in mice. Cowen
and Gmerek (3) studied the in vivo effects of metkephamid and ICI 154,129 on
charcoal meal tran sit time in mice. They found that ICI 154,129 reversed the meal
transit time slowing produced by metk ephamid. Th eir work provided in vivo pharma-
cological evidence that supports biochemical dat a that ICI 154,129 is a delta receptor
antagonist. The lack of interaction with levorph anol , a mu recep tor agonist, and
naloxone, a mu receptor antagon ist , in the gut is further evidence that IC I 154,129 is
selective for the delta receptor.
U 50,488 and ICI 154,129 are exampl es of probes of the opiate receptor that can
be used to better understand the function of each receptor and the role the opiate
system plays in controlling homeosta sis, for example, opiat e's hypotensive effect.
Holaday and Faden have done substantial work in this area . They administered
naloxone to rats in hypovolemic (4) and endotoxic (5) shock and found it to reverse the
hypotension, suggesting that the opiate receptor is involved in the pat hophysiology of
shock.
To better understand the mechani sm involved, ICI 154,129 was used (6). Rats
were injected with Escherichia coli lipopolysaccharide to induce endotox in shock.
When the mean arterial blood pressure (MABP) fell to 20-25 mm. Hg., the anim als
were injected with saline or ICI 154,129 . MABP, pulse pressure , and hear t rate were
monitored. Changes in these parameters were reversed by ICI 154,129 but not sal ine.
ICI 154,129 was ineffective in the rat tail flick test and the hot pla te test. These
findings indicate that antagonism of delt a receptors would help sta bilize blood pressure
in shock patients. Holaday, et aI., suggested that while naloxone would antagonize
delta receptors in traumatic shock patients it would also antagonize mu receptor
activity thereby exacerbating the patient's pain. By using a specific delta receptor
antagonist, endogenous analgesia mediated by enkephalin s and endorphins at the mu
receptor would be unaffected, but the patient's blood pressure would be stabilized.
Curtis and Lefer (7) also attempted to dissect the receptor mechanism involved in
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the hemodynamic stabilizing effect of naloxone. Using J 7747 , a de lta rece ptor
antagonist , C 7000, a delta receptor antagonist and kappa receptor ago nist , and M R
2266, a kappa receptor antagonist , they induced hem orrhagic shock in cats a nd
monitored MABP and myocardial depressant factor (M DF) production. M DF is a
biomolecule released by cell s in shock and contributes to the dem ise of a nimals. T heir
results showed that the delta receptor a ntagonist J 7747 had a significa ntly higher final
MABP then cats treated with the delta receptor a nta gonist, kappa receptor ago nist C
7000, a nd that cats given the kappa receptor antagonist MR 2266 did not result in a
significantly higher MABP than untreated hemorrhaged ca ts . Similar resu lts were
obtained when MDF was measured. They concluded that opiate receptors other than
the kappa receptor are involved in the pathophysiolog y of shoc k a nd tha t opia te
antagonist-ana lgesics that induce analgesia via the kappa receptor migh t be usefu l
therapeutically. U 50,488, then, might be useful in tr auma patients whe re pa in and
shock coexist.
Case studies in the lite rature have verified the effectiveness of naloxone in
pat ien ts wit h shock. T iengo (8) reporte d an eigh t year old admitt ed with sept ic shock
a nd meningococca l infection in whom int ensive therapy had failed to show improve-
ment. The patient was give n three doses of na loxone at 20- 25 minute interva ls
resulti ng in the stabilization of blood pressure at 110/65 mm. Hg. a nd hear t rate of
l lu/rninute. Init ia l values were not reported .
Wright, Phillips, an d Weller (9) presented a 33- year-old fem ale with Pseudo-
monas septicemia who was hypotensive (systolic, 50 mm. Hg.), oliguric, a nd refractory
to dopamine infusion . After naloxone was given, her blood pre ssure rose to 130/ 80 mm .
Hg ., her temperature returned to normal, a nd her urine output increased to 250
rnl.Zhour.
Dirksen and coworkers reported two patients (10) . The first was a sixty-
two-year-old fem ale with cardiogenic shock secondary to a n extensive myocard ia l
infarction whose blood pressure despite dobutamine infu sion was 50/30 mm. Hg. T he
patient was given naloxone which resulted in a blood pressure rise to 84/40 mm . Hg .
and later to 100/40 mm. Hg . A sta ble clinical condition was maintained for eleven
hours, a fter which the patient 's hemodynamic status declined a nd she died . The seco nd
patient followed a similar course. The authors have postulated a mech an ism of
na loxone action in pa tients with shock (11). Referred to as the endorphin st ress sys tem,
it t ies humoral neuroendocrine factors to homeostasis. They suggest st ress (e.g ., severe
surgica l stress, hypovolemia , a nd various forms of shock) causes release of re leasing
factors a nd subsequently proo piocortin . Proopiocortin is the prohormone precu rser
which break s down to yield adrenocorticotropic hormone (ACTH) and beta-
endorphin . ACTH acts on the adrena Is to release cortisol and beta-endorphin at th e
endorphin receptor to mediate catecholamine a nd prostaglandin rele ase. Wh ile the
evide nce for interaction bet ween the endo rphi n sys tem a nd the catecholamines is sca nt,
an endorphin an d opiate mediated, na loxone reversi ble , inhibition of PG Ei-st imulated
adenylate cyclase has been de monstrated (13) . Catecholamines a nd prostaglan din s
have been shown to play an integral role in the control of microcirculation .
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Feedback plays an important role in th is model a nd helps in und erstanding how
exogenous corticosteroids may help in the therap y of patients in shock. Massive doses
of ste roids feed back to the hypothalamus and pituitary to suppress ACTH and
beta-endor ph in release. Peters, et a l., reported a series of th irteen patients with
prolonged hypotension (14). Eight of the patients were not receiving cor ticosteroid s
and when given naloxone showed a 45% increase in systolic blood pressur e. However, in
three pat ient s receiving high doses of corticosteroids and one patient with hypoad reno-
cort icotropism following pituitary irradiation, na loxone failed to produce a pressor
response. It was felt that th e patients receivi ng high doses of corticosteroids or
suffering hypoa drenocorticotropism would have their ACTH and beta-endorphin
effectively suppressed making naloxone administra tion ineffective. Th ese clinical
findings support Dirksen 's proposed mec hanism.
Additional evidence for this neuroendocrine mech anism comes from experiments
with stress-i nduced ana lgesia in animals. Exposing rat s and mice to st ressful stimuli
suc h as elect ric foot shock, cold water swimming, centrifugal rota tion, a nd conditioned
fear produces pron ounced ana lgesia. Thi s ana lgesia is reve rsed by naloxone admi nis-
tr ati on, which implicat es th e endoge nous opia te system in its production. Panocka and
Hartmann studied the effec ts of bilateral adrena lectomy (B.A.) a nd dex am eth asone on
st ress- induced analgesia produced in mice by swimming (IS) . They separa ted mice
into fou r groups : B.A. given dexamethasone on the ninth postoperati ve day (POD-9);
B.A. given sa line on POD-9; sham adrenalectomized mice given dexamethasone on
POD-9; an d sham adrenalectomized mice given sa line on POD-9. An algesia was tested
using hind paw flick as the endpoint in the mouse hot plate test. From this da ta the
aut hors conclude that pit uita ry opiates are involved in stress-induced ana lgesia. Their
result s support Dirk sen 's mec hanism. Both adrenalectomized groups showed an
accentua tion of post- st ress analgesia. Regardl ess of the surgica l procedure performed,
dexam eth asone a ttenua ted post-stress ana lgesia. On ce feedback to the pitu ita ry is
removed (e .g., adrenalectomy) th ere is a compensatory increase in ACT H and
therefore bet a-end orphin. Likewise, with increased feed back (e.g., dexam eth asone) to
the pitui tary, AC T H and beta-endor ph in a re suppressed. Analge sia is mediat ed by the
level of beta- endorphin a t the rece ptor.
Mousa , Miller , a nd Couri examined the effect of dexam eth asone and naloxone on
cold water swimming-induced analgesia in rats (16). In thi s study, one gro up of rat s
was pre-tr eat ed with dexam eth asone for three days. Another group of rats was given
naloxone th irt y minutes pr ior to the st resso r. A third control group of ra ts received an
equ ivolume dose of sa line. Pain sensit ivity was tested by bot h the hot plate and tail flick
tests. Dexam eth asone significa ntly increased the baseline prestressor pain threshold in
the hot plate, but not th e ta il flick tests. Th e authors felt tha t the discrepancies between
the tests might be explain ed by th e discrepancies betw een detectable pain thresholds or
involvement of differ ent pain pathways in the two methods. Th ey noted a simila r
phenomenon had been reported with DMSO, neurotensin, and enk eph alin s. Pretreat -
ment with dexam eth asone produced sup pression of stressor-induced a nalgesia in both
tests. 'Naloxone administered to control rats partially antagonized the stress-induced
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analgesia . The researchers concluded that dexamethasone may act thro ugh an indi rect
mechanism to inhibit the stress-induced elevation of bet a-endorphin by acting dire ctly
on the pain-inhibiting system or via the hormones involved in tem perat ure regulation.
Data presented by different researchers indicates a clear rela tionship between
opioid and neuroendocrine system s that is probably best summa rized by the model
proposed by Dirksen and coworkers. A better understand ing of pat hophysiological
mechanisms will no doubt emerge from further investig ati on. Th e elucidation of the
endorphin stress system's function in patients with shock is an example.
Research presented in this paper demonstrates a new tie between the endogenous
opiate system and the endocrine system. This tie , in the form of proopiocort in, opens
avenues to a better understanding of stress whether induced by pain , shock, or other
factor. Perhaps one field that will greatly benefit is psychiatry. Psych iatrists are
familiar with the number of ways hum an s respond to stress (e.g. depr ession, anxi ety ,
chronic pain) . The dexamethasone suppression test (DST) currently impl ica tes a
neuroendocrine mechanism in patients suffering from depression. Depression is
frequently implicated as a cause of chronic pain. Psychi atrists believe anxiety is a
response to an internal stressor. Both fear, a response to a real external stressor, and
anxiety produce the same symptoms. What interactions with opiate and neuroendo-
crine systems may be present in anxiety? And what is the role of the opiate and
neuroendocrine systems in chronic pain? Recent research has raised speculation.
Romer and coworkers reported the synthesis of an opioid benzodiazepine (17, 18).
Benzodiazepines are widely used in the treatment of a nxiety. As with opiates, a
receptor that specifically binds benzodiazepines has been identi fied in the brain. There
has also been good correlation between receptor binding affinity and therapeutic
effect. The molecule synthesized by Romer and coworkers, while chemically a
benzodiazepine, shows no affinit y for the benzodiazepin e receptor; but rather acts
selectively on the opiate kappa receptor, acting effectiv ely as an ana lgesic and reversed
by naloxone. The research is still preliminar y, but it raises que stions about interactions
between opiate and benzodiazepine systems and their role in pain, stress, and anxi ety.
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